The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Schizophrenia Treatments Market Research Report 2024
Synopsis
Schizophrenia is a mental disorder characterized by abnormal behavior and failure to understand reality.
The global Schizophrenia Treatments market was valued at US$ 9813.9 million in 2023 and is anticipated to reach US$ 11110 million by 2030, witnessing a CAGR of 1.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Schizophrenia Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Schizophrenia Treatments.
Report Scope
The Schizophrenia Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Schizophrenia Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Schizophrenia Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Bristol-Myers Squibb
Otsuka
AstraZeneca
Sumitomo Dainippon Pharma
Eli Lilly
Alkermes
Vanda Pharmaceuticals
ALLERGAN
Pfizer
Segment by Type
Atypical Antipsychotics
Phenothiazine Antipsychotics
Thioxanthenes
Miscellaneous Antipsychotic Agents
Segment by Application
Hospital Pharmacies
Drug Stores
Retail Pharmacies
E-Commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Schizophrenia Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Schizophrenia is a mental disorder characterized by abnormal behavior and failure to understand reality.
The global Schizophrenia Treatments market was valued at US$ 9813.9 million in 2023 and is anticipated to reach US$ 11110 million by 2030, witnessing a CAGR of 1.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Schizophrenia Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Schizophrenia Treatments.
Report Scope
The Schizophrenia Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Schizophrenia Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Schizophrenia Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Bristol-Myers Squibb
Otsuka
AstraZeneca
Sumitomo Dainippon Pharma
Eli Lilly
Alkermes
Vanda Pharmaceuticals
ALLERGAN
Pfizer
Segment by Type
Atypical Antipsychotics
Phenothiazine Antipsychotics
Thioxanthenes
Miscellaneous Antipsychotic Agents
Segment by Application
Hospital Pharmacies
Drug Stores
Retail Pharmacies
E-Commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Schizophrenia Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Schizophrenia Treatments Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Atypical Antipsychotics
1.2.3 Phenothiazine Antipsychotics
1.2.4 Thioxanthenes
1.2.5 Miscellaneous Antipsychotic Agents
1.3 Market by Application
1.3.1 Global Schizophrenia Treatments Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Retail Pharmacies
1.3.5 E-Commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Schizophrenia Treatments Market Perspective (2019-2030)
2.2 Schizophrenia Treatments Growth Trends by Region
2.2.1 Global Schizophrenia Treatments Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Schizophrenia Treatments Historic Market Size by Region (2019-2024)
2.2.3 Schizophrenia Treatments Forecasted Market Size by Region (2025-2030)
2.3 Schizophrenia Treatments Market Dynamics
2.3.1 Schizophrenia Treatments Industry Trends
2.3.2 Schizophrenia Treatments Market Drivers
2.3.3 Schizophrenia Treatments Market Challenges
2.3.4 Schizophrenia Treatments Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Schizophrenia Treatments Players by Revenue
3.1.1 Global Top Schizophrenia Treatments Players by Revenue (2019-2024)
3.1.2 Global Schizophrenia Treatments Revenue Market Share by Players (2019-2024)
3.2 Global Schizophrenia Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Schizophrenia Treatments Revenue
3.4 Global Schizophrenia Treatments Market Concentration Ratio
3.4.1 Global Schizophrenia Treatments Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Schizophrenia Treatments Revenue in 2023
3.5 Schizophrenia Treatments Key Players Head office and Area Served
3.6 Key Players Schizophrenia Treatments Product Solution and Service
3.7 Date of Enter into Schizophrenia Treatments Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Schizophrenia Treatments Breakdown Data by Type
4.1 Global Schizophrenia Treatments Historic Market Size by Type (2019-2024)
4.2 Global Schizophrenia Treatments Forecasted Market Size by Type (2025-2030)
5 Schizophrenia Treatments Breakdown Data by Application
5.1 Global Schizophrenia Treatments Historic Market Size by Application (2019-2024)
5.2 Global Schizophrenia Treatments Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Schizophrenia Treatments Market Size (2019-2030)
6.2 North America Schizophrenia Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Schizophrenia Treatments Market Size by Country (2019-2024)
6.4 North America Schizophrenia Treatments Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Schizophrenia Treatments Market Size (2019-2030)
7.2 Europe Schizophrenia Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Schizophrenia Treatments Market Size by Country (2019-2024)
7.4 Europe Schizophrenia Treatments Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Schizophrenia Treatments Market Size (2019-2030)
8.2 Asia-Pacific Schizophrenia Treatments Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Schizophrenia Treatments Market Size by Region (2019-2024)
8.4 Asia-Pacific Schizophrenia Treatments Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Schizophrenia Treatments Market Size (2019-2030)
9.2 Latin America Schizophrenia Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Schizophrenia Treatments Market Size by Country (2019-2024)
9.4 Latin America Schizophrenia Treatments Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Schizophrenia Treatments Market Size (2019-2030)
10.2 Middle East & Africa Schizophrenia Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Schizophrenia Treatments Market Size by Country (2019-2024)
10.4 Middle East & Africa Schizophrenia Treatments Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Detail
11.1.2 Johnson and Johnson Business Overview
11.1.3 Johnson and Johnson Schizophrenia Treatments Introduction
11.1.4 Johnson and Johnson Revenue in Schizophrenia Treatments Business (2019-2024)
11.1.5 Johnson and Johnson Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Schizophrenia Treatments Introduction
11.2.4 Bristol-Myers Squibb Revenue in Schizophrenia Treatments Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Otsuka
11.3.1 Otsuka Company Detail
11.3.2 Otsuka Business Overview
11.3.3 Otsuka Schizophrenia Treatments Introduction
11.3.4 Otsuka Revenue in Schizophrenia Treatments Business (2019-2024)
11.3.5 Otsuka Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Schizophrenia Treatments Introduction
11.4.4 AstraZeneca Revenue in Schizophrenia Treatments Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Sumitomo Dainippon Pharma
11.5.1 Sumitomo Dainippon Pharma Company Detail
11.5.2 Sumitomo Dainippon Pharma Business Overview
11.5.3 Sumitomo Dainippon Pharma Schizophrenia Treatments Introduction
11.5.4 Sumitomo Dainippon Pharma Revenue in Schizophrenia Treatments Business (2019-2024)
11.5.5 Sumitomo Dainippon Pharma Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Schizophrenia Treatments Introduction
11.6.4 Eli Lilly Revenue in Schizophrenia Treatments Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 Alkermes
11.7.1 Alkermes Company Detail
11.7.2 Alkermes Business Overview
11.7.3 Alkermes Schizophrenia Treatments Introduction
11.7.4 Alkermes Revenue in Schizophrenia Treatments Business (2019-2024)
11.7.5 Alkermes Recent Development
11.8 Vanda Pharmaceuticals
11.8.1 Vanda Pharmaceuticals Company Detail
11.8.2 Vanda Pharmaceuticals Business Overview
11.8.3 Vanda Pharmaceuticals Schizophrenia Treatments Introduction
11.8.4 Vanda Pharmaceuticals Revenue in Schizophrenia Treatments Business (2019-2024)
11.8.5 Vanda Pharmaceuticals Recent Development
11.9 ALLERGAN
11.9.1 ALLERGAN Company Detail
11.9.2 ALLERGAN Business Overview
11.9.3 ALLERGAN Schizophrenia Treatments Introduction
11.9.4 ALLERGAN Revenue in Schizophrenia Treatments Business (2019-2024)
11.9.5 ALLERGAN Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Detail
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Schizophrenia Treatments Introduction
11.10.4 Pfizer Revenue in Schizophrenia Treatments Business (2019-2024)
11.10.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
